A detailed history of Royal Bank Of Canada transactions in 4 D Molecular Therapeutics, Inc. stock. As of the latest transaction made, Royal Bank Of Canada holds 5,396 shares of FDMT stock, worth $45,380. This represents 0.0% of its overall portfolio holdings.

Number of Shares
5,396
Previous 4,687 15.13%
Holding current value
$45,380
Previous $98,000 40.82%
% of portfolio
0.0%
Previous 0.0%

Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$10.81 - $27.22 $7,664 - $19,298
709 Added 15.13%
5,396 $58,000
Q2 2024

Aug 14, 2024

BUY
$20.93 - $30.01 $60,215 - $86,338
2,877 Added 158.95%
4,687 $98,000
Q1 2024

Nov 05, 2024

SELL
$17.03 - $35.87 $48,995 - $103,197
-2,877 Reduced 61.38%
1,810 $57,000
Q1 2024

May 15, 2024

SELL
$17.03 - $35.87 $194,601 - $409,886
-11,427 Reduced 86.33%
1,810 $57,000
Q4 2023

Feb 14, 2024

BUY
$9.76 - $21.25 $65,899 - $143,480
6,752 Added 104.12%
13,237 $268,000
Q3 2023

Nov 14, 2023

BUY
$12.64 - $19.76 $41,231 - $64,457
3,262 Added 101.21%
6,485 $82,000
Q2 2023

Aug 14, 2023

BUY
$15.16 - $23.26 $22,421 - $34,401
1,479 Added 84.81%
3,223 $58,000
Q1 2023

May 15, 2023

SELL
$15.45 - $23.19 $26,682 - $40,049
-1,727 Reduced 49.76%
1,744 $29,000
Q4 2022

Feb 14, 2023

BUY
$6.85 - $25.46 $20,796 - $77,296
3,036 Added 697.93%
3,471 $77,000
Q3 2022

Nov 14, 2022

BUY
$6.96 - $11.48 $1,572 - $2,594
226 Added 108.13%
435 $3,000
Q2 2022

Aug 15, 2022

SELL
$5.68 - $15.99 $8,786 - $24,736
-1,547 Reduced 88.1%
209 $1,000
Q1 2022

May 16, 2022

SELL
$13.16 - $22.64 $47,718 - $82,092
-3,626 Reduced 67.37%
1,756 $27,000
Q4 2021

Feb 14, 2022

BUY
$19.56 - $32.94 $59,423 - $100,071
3,038 Added 129.61%
5,382 $118,000
Q3 2021

Nov 15, 2021

BUY
$22.73 - $36.04 $37,936 - $60,150
1,669 Added 247.26%
2,344 $63,000
Q2 2021

Aug 16, 2021

BUY
$22.2 - $42.29 $14,985 - $28,545
675 New
675 $16,000

Others Institutions Holding FDMT

About 4D Molecular Therapeutics, Inc.


  • Ticker FDMT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 32,382,400
  • Market Cap $272M
  • Description
  • 4D Molecular Therapeutics, Inc., a clinical-stage gene therapy company, develops product candidates using its adeno-associated viruses vectors. It develops a portfolio of gene therapy product candidates focuses in three therapeutic areas: ophthalmology, cardiology, and pulmonology. The company has three product candidates that are in clinical tr...
More about FDMT
Track This Portfolio

Track Royal Bank Of Canada Portfolio

Follow Royal Bank Of Canada and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Royal Bank Of Canada, based on Form 13F filings with the SEC.

News

Stay updated on Royal Bank Of Canada with notifications on news.